Term
|
Definition
A. Uses
arthritis
ulcerative colitis
asthma
dermatological conditions
rhinitis
ophthalmic conditions
cancer
lupus erythematosus
infections
organ transplantation
trauma
shock
|
|
|
Term
|
Definition
1. Corticosteroids bind to glucocorticoid or
mineralocorticoid receptors, the steroid-receptor complex then regulates gene transcription.
2. Example for anti-inflammatory properties:
glucocorticoids increase lipocortin transcription
↓
lipocortin inhibits phospholipase A2
↓
decreased arachidonic acid and eicosanoids
|
|
|
Term
Brief Overview of Physiology |
|
Definition
Glucocorticoid physiology:
Increase blood glucose
Fat redistribution and lipolysis
Mineralocorticoid physiology:
Increase sodium reabsorption
Increase potassium excretion
|
|
|
Term
Structure-Activity Relationship (SAR) |
|
Definition
1. Required for activity: ketone at 3 position;
4=5 double bond
2. Small modifications in the basic corticosteroid structure alter:
a. carbohydrate-potency
b. sodium-retaining potency
c. antiinflammatory potency
d. drug half-life
e. transcortin binding
|
|
|
Term
Relative potencies of some corticosteroids (relative to hydrocortisone/cortisol)
|
|
Definition
D.Relative potencies of some corticosteroids (relative to hydrocortisone/cortisol)
1. Glucocorticoid potencies
Very High: dexamethasone ,methylprenisolone
triamcinolone
High: Prendisone
Very Low: fludrocortisone, betamethasone
2. Mineralocorticoid potencies
Very High: Fludrocortisone
High: Prednisolone , Methylprensiolone
Very Low: dexamethasone, triamcinolone, betamethasone
|
|
|
Term
Pharmacokinetics : Route of Administration |
|
Definition
1. Routes of administration
Systemic
a. oral (systemic, long-term therapy)
b. i.m. or i.v. (emergency)
Local
c. topical (eyes and skin)
d. intra-articular injection (arthritic joints)
e. inhalation (asthma)
d. nosespray (rhinitis) |
|
|
Term
Corticosteroid metabolism (liver) |
|
Definition
a. reduction of double bond at 4=5 position to yield inactive metabolite
b. conjugation of inactive metabolite
c. excretion
Liver disease affects steroid metabolism.
prednisone--------> prednisolone
(inactive) (active)
|
|
|
Term
Half-lives of some corticosteroids |
|
Definition
Short Acting(8-12 hrs): Hydrocortisone, Cortisone
Intermediate Acting(12-36): prednisolone, prendisone,triamcinolone, methylprednisolone
fludrocortisone
Long Acting (36-54) : betamethasone, dexamethasone
|
|
|
Term
Side Effects and Toxicity |
|
Definition
1. General considerations
a. route of administration: systemic vs. local
b. dosage
c. length of therapy
2. Short-term systemic
a. no serious side-effects |
|
|
Term
|
Definition
a. Cushingoid features (fat redistribution)
b. sodium retention (edema, heart failure, hypertension)
c. potassium loss (muscle weakness)
d. glucose intolerance (glycosuria/overt diabetes mellitus)
e. weight gain
f. loss of skin collagen
g. osteoporosis*
h. peptic ulcers
i. HPA axis suppression
j. CNS effects (psychosis, insomnia, nervousness, euphoria, depression)
k. susceptibility to infection
l. triamcinolone-weight loss and sedation
m. masking of symptoms of other diseases
|
|
|
Term
|
Definition
a. inhaled steroids- candidal infection of the mouth, throat irritation, dysphonia
b. nasal steroids -nasal irritation, headache, dry nose, nosebleed
c. topical- epidermal atrophy
|
|
|
Term
|
Definition
a. use smallest acceptable dose
b. goal is palliative therapy not total remission
c. shortest possible therapy (fewer side effects)
d. alternate day therapy for long-term administration
(intermediate-acting, 2X daily dose every other day in AM)
e. administer locally if possible
|
|
|
Term
|
Definition
G. Glucocorticoid Withdrawal
1. General considerations
a. dose
b. treatment length
c. steroid half-life
2. Withdrawal protocol
a. use short or intermediating-acting steroids
b. gradually taper dose (over several months)
|
|
|
Term
|
Definition
a. acute adrenal insufficiency
(1-2 wks, lasts up to 1 yr, individual specific)
b. physical dependence
(fever, malaise, myalgia, fatigue, restlessness)
c. psychological dependence
d. exacerbation of underlying disease
|
|
|
Term
|
Definition
1. Drugs that decrease steroid effectiveness
a. hepatic enzyme inducers
b. cholestyramine
2. Drugs that increase steroid effectiveness
a. certain antibiotics (erythromycin)
b. oral contraceptives
c. ketoconazole
|
|
|
Term
Drugs affected by steroid administration
|
|
Definition
a. anticoagulants (dosage increase needed)
b. antihypertensives (dosage increase needed)
c. hypoglycemics (dosage increase needed)
d. sympathomimetics (dosage decrease needed)
|
|
|